11/12/2020 4:13:19 PM
BIOLASE Q3 Loss/share $0.21 Vs. Loss $0.25 Year Ago
10/14/2020 7:34:11 AM
BIOLASE Expects Q3 Revenue To Be $6.4 Mln To $6.6 Mln, Significant Sequential Improvement
8/18/2020 6:31:34 AM
Amended: BIOLASE Regains Nasdaq Compliance For Min. Stockholder Equity, Promotes John Beaver To COO
8/13/2020 4:16:46 PM
BIOLASE Q2 Loss/share $0.12 Vs. Loss $0.18 Year Ago
7/16/2020 6:31:10 AM
BIOLASE Reports Expiration Of Oversubscribed Rights Offering
7/13/2020 8:13:35 AM
BIOLASE Says REPAIR Perio Protocol Superior For Procedure Time And Patient-Reported Outcomes
7/8/2020 9:04:46 AM
Biolase Says Epic Hygiene Laser Meets Guidelines To Minimize Risk Of COVID-19 Transmission
6/22/2020 6:34:44 AM
BIOLASE Provides Update To Stockholders For Proposed Rights And Expected Key Dates And Terms Related To Offering
6/11/2020 6:31:28 AM
BIOLASE Closes $6.9 Mln Registered Direct Offering Priced At-The-Market
6/8/2020 11:02:56 AM
BIOLASE Prices $6.9 Mln Direct Offering Priced At-The-Market
3/26/2020 4:09:47 PM
BIOLASE Q4 Loss/share $0.13 Vs. Loss $0.33 Year Ago
3/24/2020 9:22:47 AM
BIOLASE Announces Regulatory Clearance Of Laser Bacterial Reduction Therapy Indication For Epic Hygiene Laser
11/15/2019 6:33:19 AM
BIOLASE Appoints Michael DiTolla To Board
10/21/2019 7:05:20 AM
BIOLASE Sees Q3 Revenue Of $8.5 Mln To $8.8 Mln